vs
Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $885.8M, roughly 1.7× BWX Technologies, Inc.). BWX Technologies, Inc. runs the higher net margin — 10.5% vs -13.6%, a 24.1% gap on every dollar of revenue. On growth, BWX Technologies, Inc. posted the faster year-over-year revenue change (18.7% vs -5.3%). Organon & Co. produced more free cash flow last quarter ($96.0M vs $56.8M). Over the past eight quarters, BWX Technologies, Inc.'s revenue compounded faster (21.1% CAGR vs -3.6%).
BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
BWXT vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $885.8M | $1.5B |
| Net Profit | $93.0M | $-205.0M |
| Gross Margin | — | 49.2% |
| Operating Margin | 10.4% | -9.8% |
| Net Margin | 10.5% | -13.6% |
| Revenue YoY | 18.7% | -5.3% |
| Net Profit YoY | 30.9% | -288.1% |
| EPS (diluted) | $1.02 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $885.8M | $1.5B | ||
| Q3 25 | $866.3M | $1.6B | ||
| Q2 25 | $764.0M | $1.6B | ||
| Q1 25 | $682.3M | $1.5B | ||
| Q4 24 | $746.3M | $1.6B | ||
| Q3 24 | $672.0M | $1.6B | ||
| Q2 24 | $681.5M | $1.6B | ||
| Q1 24 | $604.0M | $1.6B |
| Q4 25 | $93.0M | $-205.0M | ||
| Q3 25 | $82.1M | $160.0M | ||
| Q2 25 | $78.4M | $145.0M | ||
| Q1 25 | $75.5M | $87.0M | ||
| Q4 24 | $71.0M | $109.0M | ||
| Q3 24 | $69.5M | $359.0M | ||
| Q2 24 | $73.0M | $195.0M | ||
| Q1 24 | $68.5M | $201.0M |
| Q4 25 | — | 49.2% | ||
| Q3 25 | 21.8% | 53.5% | ||
| Q2 25 | 25.1% | 54.8% | ||
| Q1 25 | 24.2% | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | 24.4% | 58.3% | ||
| Q2 24 | 24.7% | 58.4% | ||
| Q1 24 | 24.6% | 59.0% |
| Q4 25 | 10.4% | -9.8% | ||
| Q3 25 | 13.1% | 15.2% | ||
| Q2 25 | 13.4% | 14.4% | ||
| Q1 25 | 14.2% | 6.7% | ||
| Q4 24 | 12.4% | 8.1% | ||
| Q3 24 | 14.4% | 13.1% | ||
| Q2 24 | 14.5% | 14.6% | ||
| Q1 24 | 15.4% | 14.5% |
| Q4 25 | 10.5% | -13.6% | ||
| Q3 25 | 9.5% | 10.0% | ||
| Q2 25 | 10.3% | 9.1% | ||
| Q1 25 | 11.1% | 5.8% | ||
| Q4 24 | 9.5% | 6.8% | ||
| Q3 24 | 10.3% | 22.7% | ||
| Q2 24 | 10.7% | 12.1% | ||
| Q1 24 | 11.3% | 12.4% |
| Q4 25 | $1.02 | $-0.78 | ||
| Q3 25 | $0.89 | $0.61 | ||
| Q2 25 | $0.85 | $0.56 | ||
| Q1 25 | $0.82 | $0.33 | ||
| Q4 24 | $0.77 | $0.42 | ||
| Q3 24 | $0.76 | $1.38 | ||
| Q2 24 | $0.79 | $0.75 | ||
| Q1 24 | $0.75 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $499.8M | $574.0M |
| Total DebtLower is stronger | — | $8.6B |
| Stockholders' EquityBook value | $1.2B | $752.0M |
| Total Assets | $4.3B | $12.9B |
| Debt / EquityLower = less leverage | — | 11.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $499.8M | $574.0M | ||
| Q3 25 | $79.6M | $672.0M | ||
| Q2 25 | $37.0M | $599.0M | ||
| Q1 25 | $55.4M | $547.0M | ||
| Q4 24 | $74.1M | $675.0M | ||
| Q3 24 | $35.5M | $763.0M | ||
| Q2 24 | $48.3M | $704.0M | ||
| Q1 24 | $45.9M | $575.0M |
| Q4 25 | — | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B | ||
| Q1 24 | — | $8.7B |
| Q4 25 | $1.2B | $752.0M | ||
| Q3 25 | $1.2B | $906.0M | ||
| Q2 25 | $1.2B | $733.0M | ||
| Q1 25 | $1.1B | $542.0M | ||
| Q4 24 | $1.1B | $472.0M | ||
| Q3 24 | $1.1B | $493.0M | ||
| Q2 24 | $998.5M | $144.0M | ||
| Q1 24 | $946.2M | $48.0M |
| Q4 25 | $4.3B | $12.9B | ||
| Q3 25 | $3.8B | $13.6B | ||
| Q2 25 | $3.7B | $13.5B | ||
| Q1 25 | $3.1B | $13.2B | ||
| Q4 24 | $2.9B | $13.1B | ||
| Q3 24 | $2.9B | $12.8B | ||
| Q2 24 | $2.8B | $12.2B | ||
| Q1 24 | $2.8B | $11.9B |
| Q4 25 | — | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× | ||
| Q1 24 | — | 181.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $127.0M | $141.0M |
| Free Cash FlowOCF − Capex | $56.8M | $96.0M |
| FCF MarginFCF / Revenue | 6.4% | 6.4% |
| Capex IntensityCapex / Revenue | 7.9% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | $295.3M | $538.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $127.0M | $141.0M | ||
| Q3 25 | $143.2M | $264.0M | ||
| Q2 25 | $159.0M | $220.0M | ||
| Q1 25 | $50.6M | $75.0M | ||
| Q4 24 | $276.9M | $390.0M | ||
| Q3 24 | $32.6M | $141.0M | ||
| Q2 24 | $65.9M | $332.0M | ||
| Q1 24 | $33.0M | $76.0M |
| Q4 25 | $56.8M | $96.0M | ||
| Q3 25 | $94.9M | $218.0M | ||
| Q2 25 | $126.3M | $181.0M | ||
| Q1 25 | $17.3M | $43.0M | ||
| Q4 24 | $224.4M | $335.0M | ||
| Q3 24 | $-7.7M | $99.0M | ||
| Q2 24 | $35.5M | $300.0M | ||
| Q1 24 | $2.6M | $30.0M |
| Q4 25 | 6.4% | 6.4% | ||
| Q3 25 | 11.0% | 13.6% | ||
| Q2 25 | 16.5% | 11.4% | ||
| Q1 25 | 2.5% | 2.8% | ||
| Q4 24 | 30.1% | 21.0% | ||
| Q3 24 | -1.1% | 6.3% | ||
| Q2 24 | 5.2% | 18.7% | ||
| Q1 24 | 0.4% | 1.8% |
| Q4 25 | 7.9% | 3.0% | ||
| Q3 25 | 5.6% | 2.9% | ||
| Q2 25 | 4.3% | 2.4% | ||
| Q1 25 | 4.9% | 2.1% | ||
| Q4 24 | 7.0% | 3.5% | ||
| Q3 24 | 6.0% | 2.7% | ||
| Q2 24 | 4.5% | 2.0% | ||
| Q1 24 | 5.0% | 2.8% |
| Q4 25 | 1.37× | — | ||
| Q3 25 | 1.74× | 1.65× | ||
| Q2 25 | 2.03× | 1.52× | ||
| Q1 25 | 0.67× | 0.86× | ||
| Q4 24 | 3.90× | 3.58× | ||
| Q3 24 | 0.47× | 0.39× | ||
| Q2 24 | 0.90× | 1.70× | ||
| Q1 24 | 0.48× | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BWXT
| Nuclear Component Program | $436.4M | 49% |
| Nuclear Manufacturing | $134.8M | 15% |
| Cost Plus Fee | $116.1M | 13% |
| Uranium And Nuclear Services | $103.8M | 12% |
| Commercial Operations | $49.0M | 6% |
| Commercial Operations Segment | $33.7M | 4% |
| Transferred At Point In Time | $1.3M | 0% |
OGN
Segment breakdown not available.
